Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) was up 9.7% during mid-day trading on Thursday . The stock traded as high as $13.39 and last traded at $13.44. Approximately 455,832 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 1,298,486 shares. The stock had previously closed at $12.25.
Ginkgo Bioworks Stock Down 3.4 %
The stock's 50 day moving average is $10.44. The firm has a market cap of $741.78 million, a price-to-earnings ratio of -0.99 and a beta of 1.16.
Hedge Funds Weigh In On Ginkgo Bioworks
Several institutional investors and hedge funds have recently made changes to their positions in DNA. Palumbo Wealth Management LLC purchased a new stake in Ginkgo Bioworks in the fourth quarter worth about $144,000. Forbes J M & Co. LLP boosted its position in shares of Ginkgo Bioworks by 461.4% during the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock valued at $6,891,000 after purchasing an additional 576,732 shares in the last quarter. KBC Group NV purchased a new stake in Ginkgo Bioworks in the fourth quarter worth $31,000. SG Americas Securities LLC bought a new position in Ginkgo Bioworks in the fourth quarter worth $199,000. Finally, FNY Investment Advisers LLC lifted its position in Ginkgo Bioworks by 125.6% during the fourth quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company's stock valued at $745,000 after buying an additional 42,298 shares during the period. Institutional investors own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
